AMY GOTVASLEE: Open Payments
NPI 1396157830 · BISMARCK, ND. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,298 in 81 payments from 21 companies in 2025. Trend: 2023 $960 · 2024 $923 · 2025 $1,298
Food & beverage: $1,298
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 16 | $204 |
| Amgen Inc. | 12 | $153 |
| Lilly USA, LLC | 10 | $133 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $112 |
| Novartis Pharmaceuticals Corporation | 6 | $109 |
| Dexcom, Inc. | 5 | $105 |
| Novo Nordisk Inc | 4 | $62 |
| Astellas Pharma US Inc | 3 | $62 |
| E.R. Squibb & Sons, L.L.C. | 3 | $60 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $42 |
Products named: VRAYLAR, LEQVIO, Dexcom G6 Transmitter, MOUNJARO, OTEZLA, EVENITY, Veozah, CAMZYOS.
Industry payments across ND — which companies pay providers there.
